Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Basal medication AND Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    158 result(s) found for: Basal medication AND Placebo. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2018-001462-42 Sponsor Protocol Number: Pelle-926-301 Start Date*: 2019-01-22
    Sponsor Name:PellePharm, Inc.
    Full Title: A Multicenter, Randomized, Double blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cel...
    Medical condition: Basal Cell Nevus Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10004151 Basal cell nevus syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing) NL (Completed) DE (Completed) DK (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003502-33 Sponsor Protocol Number: D5553C00002 Start Date*: 2014-12-16
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glarg...
    Medical condition: Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-005439-26 Sponsor Protocol Number: NL47392.068.13 Start Date*: 2014-04-23
    Sponsor Name:Maastricht University Medical Centre
    Full Title: Topical sinecatechins ointment in treatment of primary superficial Basal Cell Carcinoma: a double blind, randomized, placebo-controlled trial.
    Medical condition: Primary histological proven superficial basal cell carcinoma ≥ 4mm < 20mm outside the H-zone of the face or scalp
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10042503 Superficial basal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001969-27 Sponsor Protocol Number: GLP111892 Start Date*: 2014-11-19
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Albiglutide Versus Placebo as Add-on to Intensified Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002121-36 Sponsor Protocol Number: 0941-007 Start Date*: 2008-07-11
    Sponsor Name:MSD Finland Oy
    Full Title: A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose- Range Finding Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control o...
    Medical condition: Treatment of Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) AT (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended) HU (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000275-14 Sponsor Protocol Number: GB29260 Start Date*: 2014-08-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II, randomized, double-blind, placebo-controlled bronchoscopy study to evaluate the effects of Lebrikizumab on airway eosinophilic inflammation in patients with uncontrolled asthma on inhal...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003123-22 Sponsor Protocol Number: JCS-CBG-2014-01 Start Date*: 2015-01-02
    Sponsor Name:José Castillo Sanchez
    Full Title: "Randomized clinical trial with two parallel groups, double-blind, placebo-controlled trial to investigate whether administration of CBG000592 (riboflavin/vitamin B2) in patients with acute ischemi...
    Medical condition: Acute ischemic stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002952-34 Sponsor Protocol Number: NN9924-4437 Start Date*: 2020-09-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Ongoing) PT (Ongoing) GR (Ongoing) NL (Ongoing) AT (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023799-21 Sponsor Protocol Number: H9X-MC-GBDJ Start Date*: 2011-10-06
    Sponsor Name:Eli Lilly & Company
    Full Title: The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)
    Medical condition: Cardiovascular events in patients with Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004860 10012654 Diabetic complications cardiovascular HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed) GB (Completed) PL (Completed) ES (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001661-15 Sponsor Protocol Number: 087-CL-089 Start Date*: 2007-10-11
    Sponsor Name:Astellas Pharma US, Inc
    Full Title: A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Assess the Safety and Effects of Intravenous Conivaptan on the Hepatic Hemodynamic Response in Stable Euvolemic or ...
    Medical condition: stable euvolemic or hypervolemic cirrhotic patients with serum sodium 115 – 140 mEq/L Pacientes cirróticos euvolémicos o hipervolémicos estables con un valor de sodio sérico comprendido entre 115 ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019641 Hepatic cirrhosis PT
    9.1 10021038 Hyponatremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-002414-39 Sponsor Protocol Number: MK-3102-018 Start Date*: 2013-01-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Prematurely Ended) DE (Completed) NO (Completed) SE (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) ES (Prematurely Ended) FI (Completed) DK (Prematurely Ended) IT (Completed) BE (Completed) SK (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002259-14 Sponsor Protocol Number: TRG12-05 Start Date*: 2013-11-27
    Sponsor Name:University of Oxford
    Full Title: The effect of lixisenatide in type 1 diabetes
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005186-10 Sponsor Protocol Number: EGF105485 Start Date*: 2006-09-12
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2 Overexpressing Breast Cancer
    Medical condition: Women with early-stage ErbB2-overexpressing breast cancer. Eligible women must have had an initial diagnosis of histologically or cytologically confirmed invasive breast cancer (Stage I through St...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) LT (Completed) ES (Completed) BE (Completed) DK (Completed) LV (Completed) GR (Completed) SK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001887-46 Sponsor Protocol Number: STH18493 Start Date*: 2018-11-08
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial to assess the safety and tolerability Of 30mg/kg daily Ursodeoxycholic Acid (UDCA) in Patients with Parkinson’s Disease (PD)
    Medical condition: Parkinson’s disease (PD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2004-000630-37 Sponsor Protocol Number: 308601 Start Date*: 2004-11-29
    Sponsor Name:Schering AG
    Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety, tolerability and efficacy of the CCR1 antagonist ZK 811752, given orally in a dose of 600 m...
    Medical condition: Endometrial pain
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) SE (Completed) ES (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-003843-36 Sponsor Protocol Number: H8O-US-GWCO Start Date*: 2008-09-19
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Trial Comparing Exenatide with Placebo in Subjects with Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021870-12 Sponsor Protocol Number: 10TASQ10 Start Date*: 2011-02-15
    Sponsor Name:Active Biotech AB
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate Resistant Prostate Cancer
    Medical condition: Metastatic Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (Completed) BE (Completed) DE (Completed) LV (Completed) NL (Completed) CZ (Completed) ES (Completed) LT (Completed) IT (Completed) SK (Completed) GR (Completed) EE (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-002825-22 Sponsor Protocol Number: PROPUDO Start Date*: 2011-12-29
    Sponsor Name:Hospital General Universitario de Alicante
    Full Title: Pilot, placebo-controlled, double-blind, randomized, parallel propofol effective in preventing refractory chronic migraine
    Medical condition: Refractory chronic migraine
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000821-37 Sponsor Protocol Number: O3NPIQ Start Date*: 2019-12-10
    Sponsor Name:Bernardino Clavo - Hospital Universitario de G. C. Dr. Negrín
    Full Title: Effectiveness and cost-effectiveness of Ozone therapy in patients with pain secondary to chemotherapy-induced peripheral neuropathy. Randomized, triple-blind clinical trial.
    Medical condition: Pain secondary to chemotherapy-induced peripheral neuropathy.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10079545 Chemotherapy induced peripheral neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004646-98 Sponsor Protocol Number: TRICA_L_04286 Start Date*: 2015-03-17
    Sponsor Name:Sanofi
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 μg...
    Medical condition: Rhinitis, Allergic, Perennial and/or Seasonal
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 27 22:45:09 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA